Tarsons Products Limited announced the outcome of its Board Meeting held on February 06, 2026. The board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Furthermore, the company decided to infuse an additional EUR 3 Million (approximately ₹27 crore) into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., to meet operational and financial expenses. This infusion is to be completed in quarterly tranches by March 31, 2027. In a significant board change, Mr. Vinesh Mohan Kriplani was appointed as an Additional Director (Non-Executive Independent Director) effective February 06, 2026, for a term of five years, subject to shareholder approval. Mr. Kriplani brings over 29 years of experience in corporate and international taxation, mergers, and acquisitions. Concurrently, Mr. Girish Paman Vanvari resigned as an Independent Director, effective February 06, 2026, due to personal commitments. His resignation also led to his cessation as chairperson of the Audit Committee & Risk Management Committee and member of the Nomination and Remuneration Committee. Following these changes, the Board of Directors reconstituted the Audit Committee, Nomination and Remuneration Committee, and Risk Management Committee.
